Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.e. ChAdOx1 nCoV-19 (AstraZeneca), have recently been approved in Europe. Clinical trials on these vaccines have been published on the general population showing a high efficacy with minor adverse events. However, specific data about the efficacy and safety of these vaccines in patients with immune-mediated inflammatory diseases (IMIDs) are still lacking. Moreover, the limited availability of these vaccines requires prioritizing some vulnerable categories of patients compared to others. In this position paper, we propose the point of view about the management of COVID-19 vaccination from Italian experts on IMIDs and the identification of high-risk groups according to the different diseases and their chronic therapy.

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group / F. Ferretti, R. Cannatelli, M. Benucci, S. Carmagnola, E. Clementi, P. Danelli, D. Dilillo, P. Fiorina, M. Galli, M. Gallieni, G. Genovese, V. Giorgi, A. Invernizzi, G. Maconi, J.A. Maier, A.V. Marzano, P.S. Morpurgo, M. Nebuloni, D. Radovanovic, A. Riva, G. Rizzardini, G. Sabiu, P. Santus, G. Staurenghi, G. Zuccotti, P.C. Sarzi-Puttini, S. Ardizzone. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 12(2021), pp. 656362.1-656362.14. [10.3389/fimmu.2021.656362]

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

F. Ferretti
Primo
;
R. Cannatelli;S. Carmagnola;E. Clementi;P. Danelli;P. Fiorina;M. Galli;M. Gallieni;G. Genovese;A. Invernizzi;G. Maconi;J.A. Maier;A.V. Marzano;M. Nebuloni;D. Radovanovic;A. Riva;G. Sabiu;P. Santus;G. Staurenghi;G. Zuccotti;P.C. Sarzi-Puttini;S. Ardizzone
Ultimo
2021

Abstract

Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.e. ChAdOx1 nCoV-19 (AstraZeneca), have recently been approved in Europe. Clinical trials on these vaccines have been published on the general population showing a high efficacy with minor adverse events. However, specific data about the efficacy and safety of these vaccines in patients with immune-mediated inflammatory diseases (IMIDs) are still lacking. Moreover, the limited availability of these vaccines requires prioritizing some vulnerable categories of patients compared to others. In this position paper, we propose the point of view about the management of COVID-19 vaccination from Italian experts on IMIDs and the identification of high-risk groups according to the different diseases and their chronic therapy.
chronic disease; COVID-19; IMIDs; prevention; Sars-CoV-2; vaccine; COVID-19; COVID-19 Vaccines; Diabetes Mellitus; Europe; Expert Testimony; Glomerulonephritis; Humans; Immune System Diseases; Inflammation; Inflammatory Bowel Diseases; Lung Diseases; Pandemics; Rheumatic Diseases; Skin Diseases; Uveitis; Vaccination
Settore MED/35 - Malattie Cutanee e Veneree
Settore MED/09 - Medicina Interna
Settore MED/30 - Malattie Apparato Visivo
Settore MED/14 - Nefrologia
Settore MED/16 - Reumatologia
Settore MED/12 - Gastroenterologia
Settore MED/17 - Malattie Infettive
Settore MED/13 - Endocrinologia
Settore MED/18 - Chirurgia Generale
Settore BIO/14 - Farmacologia
Settore MED/08 - Anatomia Patologica
Settore MED/04 - Patologia Generale
Settore MED/10 - Malattie dell'Apparato Respiratorio
Settore MED/38 - Pediatria Generale e Specialistica
Article (author)
File in questo prodotto:
File Dimensione Formato  
fimmu-12-656362.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 548.91 kB
Formato Adobe PDF
548.91 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/838023
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 20
social impact